1. Australia Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Antisense Therapeutics Limited

Antisense Therapeutics Limited

ATHJF
Antisense Therapeutics LimitedUS flagOther OTC
0.01
USD
-0.04
- -
19.64MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
Revenue per Share
- -
- -
- -
0.02
0.01
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.02
-0.02
-0.02
- -
-0.01
-0.02
-0.01
-0.01
-0.01
-0.01
-0.01
-0.02
- -
Free Cash Flow per Basic Share
-0.02
-0.02
-0.02
0.01
-0.01
-0.02
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.04
0.02
0.01
0.04
0.02
0.01
0.02
0.01
- -
- -
0.03
0.01
- -
Tangible Book Value per Share
0.05
0.03
0.01
0.04
0.03
0.01
0.02
0.01
0.01
0.01
0.03
0.01
- -
Basic Weighted Avg Shares
105
144
147
161
179
165
195
386
456
541
634
669
- -
Sales/Revenue/Turnover
- -
- -
- -
4
1
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
-0.65
-307.24
-4,655.44
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-2
-3
1
-3
-3
-2
-3
-6
-8
-6
-11
-12
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
18.3
-251.44
-3,985.82
- -
- -
- -
- -
- -
- -
- -
Working Capital
5
5
2
7
5
2
4
3
4
6
21
10
9
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
5
5
2
7
5
2
4
3
5
6
21
10
9
Return on Invested Capital (%)
- -
- -
- -
-0.54
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
19.35
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-79.14
-66.29
-130.1
19.48
-51.59
-100.73
-76.75
-83.76
-240.14
-398.35
-60.66
-98.11
-175.1

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
53.7%
59.57%
-6.14%
Free Cash Flow
- -
77.89%
-87.69%
Net Income, GAAP
-34.89%
41.95%
4.74%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
-0.01
2023
- -
- -
- -
- -
-0.02
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
James Garner MBA
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
14 Wallace Avenue Toorak VIC Australia 3142
IPO Date
Sep 8, 2009
Website
antisense.com.au
Similar Companies
Leef Brands Inc. (LEEF.CN)
Shandong Wohua Pharmaceutical Co., Ltd. (002107.SZ)
Bafna Pharmaceuticals Limited (BAFNAPH.NS)
MJardin Group, Inc. (MJARF)
Gujarat Themis Biosyn Ltd. (GUJTHEM.NS)
IM Cannabis Corp. (IMCC)
Business
Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is an Australian-listed biopharmaceutical company that develops and commercializes antisense oligonucleotide therapies for rare diseases with significant unmet needs, including Duchenne muscular dystrophy, multiple sclerosis, and acromegaly; its products are in-licensed from Ionis Pharmaceuticals Inc. The company's lead candidate, ATL1102, is an antisense inhibitor of the CD49d receptor investigated as a targeted anti-inflammatory therapy via weekly subcutaneous injection for non-ambulatory Duchenne muscular dystrophy patients, with prior Phase II results showing preservation of upper limb function and promising safety; it has also demonstrated efficacy in reducing brain lesions in relapsing-remitting multiple sclerosis and holds US FDA Orphan Drug Designation for DMD. Additional pipeline assets include ATL1103 (Atesidorsen), an antisense oligonucleotide targeting growth hormone receptor expression to lower insulin-like growth factor-I levels for acromegaly and related disorders, following successful Phase II trials. Founded in 2000 and headquartered in Toorak, Victoria, Australia, the company operates primarily in Australia with global clinical development programs targeting international regulatory approvals, such as the EMA-agreed Paediatric Investigation Plan for ATL1102's planned Phase IIb/III trial in Europe. Recent developments include the appointment of Dr. James Garner as CEO and Managing Director effective August 2023; a capital raise in 2023 to fund the DMD trial through key milestones; and a name change to Percheron Therapeutics Limited approved by shareholders in November 2023 and implemented in December 2023 to reflect its evolved strategy.